ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, ...
Speedskater Erin Jackson, who won a gold medal at the 2022 Beijing Winter Olympics, talks about how eczema has affected her, ...
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...
Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...
ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, Connect or the Company ...
There are some 40 interleukins that play a wide variety of roles in inflammation and the body’s immune response, some of them hitting the accelerator and others tapping the brakes. When it comes to ...
Q: My doctor just told me that I’m now considered obese. A week ago, I wasn’t — and I haven’t gained any weight. What’s going ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback